Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint b...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2021/6661406 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560021489057792 |
|---|---|
| author | Rangarirai Makuku Neda Khalili Sepideh Razi Mahsa Keshavarz-Fathi Nima Rezaei |
| author_facet | Rangarirai Makuku Neda Khalili Sepideh Razi Mahsa Keshavarz-Fathi Nima Rezaei |
| author_sort | Rangarirai Makuku |
| collection | DOAJ |
| description | Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint blockade through targeting programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects in cancer immunotherapy of many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability. In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy. We also discuss the adverse events associated with PD-1/L1/2 inhibitors, ranging from severe life-threatening conditions such as autoimmune myocarditis to mild and moderate reactions such as skin rashes, and explore the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors. |
| format | Article |
| id | doaj-art-1ecccf248b544ac38986f344edc2ebbb |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-1ecccf248b544ac38986f344edc2ebbb2025-02-03T01:28:29ZengWileyJournal of Immunology Research2314-88612314-71562021-01-01202110.1155/2021/66614066661406Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer ImmunotherapyRangarirai Makuku0Neda Khalili1Sepideh Razi2Mahsa Keshavarz-Fathi3Nima Rezaei4Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, IranCancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, IranCancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, IranCancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, IranDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, IranCancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint blockade through targeting programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects in cancer immunotherapy of many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability. In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy. We also discuss the adverse events associated with PD-1/L1/2 inhibitors, ranging from severe life-threatening conditions such as autoimmune myocarditis to mild and moderate reactions such as skin rashes, and explore the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors.http://dx.doi.org/10.1155/2021/6661406 |
| spellingShingle | Rangarirai Makuku Neda Khalili Sepideh Razi Mahsa Keshavarz-Fathi Nima Rezaei Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy Journal of Immunology Research |
| title | Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy |
| title_full | Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy |
| title_fullStr | Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy |
| title_full_unstemmed | Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy |
| title_short | Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy |
| title_sort | current and future perspectives of pd 1 pdl 1 blockade in cancer immunotherapy |
| url | http://dx.doi.org/10.1155/2021/6661406 |
| work_keys_str_mv | AT rangariraimakuku currentandfutureperspectivesofpd1pdl1blockadeincancerimmunotherapy AT nedakhalili currentandfutureperspectivesofpd1pdl1blockadeincancerimmunotherapy AT sepidehrazi currentandfutureperspectivesofpd1pdl1blockadeincancerimmunotherapy AT mahsakeshavarzfathi currentandfutureperspectivesofpd1pdl1blockadeincancerimmunotherapy AT nimarezaei currentandfutureperspectivesofpd1pdl1blockadeincancerimmunotherapy |